GENGLYCOS FDA Approval Secured, But Durability Gap and HTA Complexity Define the Real Commercial Test

Ultragenyx Publishes Positive 96-Week GENGLYCOS Data in GSDIa

Ultragenyx announced the publication of 96-week data from its Phase 3 GlucoGene study of GENGLYCOS (pariglasgene brecaparvovec-opnr) AAV gene therapy for glycogen storage disease type Ia (GSDIa) in The Journal of Inherited Metabolic Disease. The study demonstrated a mean reduction in daily cornstarch intake of 61% from baseline across treatment and crossover groups at Week 96, while maintaining glycemic control. Notably, 33% of the original DTX401 group and 42% of the crossover group achieved complete elimination of nighttime cornstarch dosing. The therapy, recently approved by the FDA for GSDIa patients aged eight and older, also showed an acceptable safety profile.

• Sustained Efficacy and Glycemic Control: At Week 96, participants treated with GENGLYCOS achieved a significant mean reduction of 61% in daily cornstarch intake from baseline, building upon the 41% reduction at Week 48 (p < 0.0001 vs placebo). This reduction was achieved while maintaining low levels of hypoglycemia and improved euglycemic range, indicating the liver's enhanced ability to regulate glucose production and offering protection from severe hypoglycemia.
• Reduced Nighttime Treatment Burden and Patient Impact: The study highlighted a substantial reduction in nighttime cornstarch use, a major burden for GSDIa patients. By Week 96, 67% of participants in both treatment groups eliminated at least one nighttime cornstarch dose, with 33% of the original DTX401 group and 42% of the crossover group completely eliminating it. Patient-reported outcomes confirmed the clinical meaningfulness, with 83% of participants meeting or exceeding their expectations for cornstarch reduction at Week 48, improving to 95% in the crossover group by Week 96.
• Favorable Safety Profile and Nutritional Benefits: GENGLYCOS demonstrated an acceptable and manageable safety profile, consistent with previous findings. The most common adverse events were transient elevations in liver enzymes, managed with prophylactic corticosteroids. The therapy also enabled participants to transition from a cornstarch-heavy diet (nearly 50% of caloric intake) to a more balanced, food-based diet, aligning closer to general population dietary guidelines, further enhancing quality of life.

Addressing the Burden and Unmet Needs in GSDIa Management

GSDIa imposes a substantial and multifaceted burden on patients, arising from both the inherent pathophysiology of the disease and the limitations of available therapeutic strategies. Current dietary management, while essential for survival, falls short of preventing the full spectrum of disease complications, and emerging gene therapy approaches carry their own implementation challenges.

• Dietary management cannot prevent long-term hepatic complications. Dietary therapies for GSDIa, including frequent consumption of uncooked cornstarch to maintain blood glucose levels, are available but cannot prevent the long-term complication of hepatocellular adenoma, which may undergo malignant transformation to hepatocellular carcinoma. This risk persists even in patients with mild disease who have not experienced recurrent hypoglycemic episodes.

• Significant and progressive complication burden despite treatment. Patients with GSDIa experience numerous serious complications, including hepatocellular adenoma (odds ratio 305.9), liver transplantation (164.6), acidosis (45.5), hepatomegaly (43.6), hyperuricemia (23.6), and hypoglycemia (20.2) compared to matched non-GSDIa comparators. Chronic complications such as gout, osteoarthritis, chronic kidney disease, and neoplasms are more common in adults, while acute complications including poor growth, gastrostomy, seizure, and hypoglycemia are more common in children, reflecting the progressive nature of the disease across the lifespan.

• High resource utilization and healthcare costs. GSDIa patients require substantially more healthcare resources than comparators, including more hospitalizations (0.53 vs 0.06 hospitalizations per patient per year), with 26.6% vs 2.3% requiring 2 or more hospitalizations, longer length of stay (3.1 vs 0.4 days), and 4.3 times more emergency department visits annually. Mean annual total healthcare costs were almost 8 times higher than those of comparators.

• Metabolic complications of hyperlipidemia are difficult to control. GSDIa patients exhibit significant abnormalities in lipid metabolism, including hypertriglyceridemia, which elevates the risk of acute pancreatitis — a potentially life-threatening complication. Raw cornstarch treatment reduced total triglycerides significantly (from 8.37±7.23 to 5.39±5.29 mmol/L, p<0.001), but did not change total cholesterol levels, indicating that dietary management alone provides incomplete lipid control.

• Gene therapy implementation requires careful dietary transition management. Following DTX401 (pariglasgene brecaparvovec) treatment in an open-label phase 1/2 trial, 4 of 7 participants (57%) reported at least one negative change attributed to instances of blood sugar instability, lifestyle, or diet adjustments. Interview results suggest that guidance on and close monitoring of dietary changes during implementation should be provided to optimize patient outcomes and experience with gene therapy.

• Early detection remains a barrier to timely intervention. Gene replacement therapy requires early treatment in infancy for safety and efficiency, yet screening systems capable of detecting causative mutations such as c.648G>T in the G6PC gene in newborns are only now being developed, with real-world newborn screening applicability still being established.

GENGLYCOS Delivers Significant Reductions in Cornstarch Dependence

The investigational gene therapy DTX401 (pariglasgene brecaparvovec), an adeno-associated virus serotype 8 vector (AAV8)-based therapy designed to restore endogenous glucose production, has been evaluated in an open-label, phase 1/2 dose-escalation trial (NCT03517085) in adults aged ≥18 years with GSDIa. In that trial, 86% (n = 6/7) of participants reported overall symptom improvement and reduced burden following DTX401 treatment. Satisfaction with gene therapy was reported by 80% of participants at Week 24, 86% at Week 52, and 86% at Week 104, with no participants reporting being very dissatisfied at any timepoint.

Most interviewees described substantial reductions in cornstarch intake alongside improvements across multiple domains, including physical function, diet management, emotional function, self-perception, social function, sleep quality, work performance, and overall health. Three participants (43%) reported no negative outcomes following gene therapy, while 4 (57%) mentioned at least one negative change attributed to instances of blood sugar instability, lifestyle, or diet adjustments. Notably, most participants indicated they would still want gene therapy even if they had to continue cornstarch or maintain continued diet restrictions.

The knowledge base does not have sufficient information on this aspect.

Sustained Efficacy and Manageable Safety Profile for GENGLYCOS

Published data on long-term outcomes in GSDIa spans both dietary management strategies and emerging gene therapy approaches. The phase 1/2, open-label, 52-week dose-escalation trial of DTX401 (pariglasgene brecaparvovec), an AAV8-based gene therapy expressing the human G6PC1 gene, enrolled 12 adults with GSDIa across four cohorts receiving either 2.0 × 10 or 6.0 × 10 genome copies/kg. At Week 52, mean total daily cornstarch intake fell from 284 g at baseline to 85 g in the 10 participants with available values at both time points, representing a mean (SD) total daily cornstarch intake reduction of 68% (20%); p < 0.001. Mean (SD) time to hypoglycemia during a controlled fasting challenge increased from 5.0 (1.6) minutes/gram of carbohydrate at baseline to 6.9 (2.7) at Week 52, a mean (SD) increase of 46% (72%). No participant experienced a dose-limiting toxicity, a treatment-emergent adverse event (TEAE) leading to study discontinuation, a TEAE leading to death, or a serious treatment-related TEAE, supporting a favorable safety and efficacy profile at Week 52. Patient experience interviews conducted at Weeks 24, 52, and 104 as part of the same trial found that 86% (n = 6/7) of participants reported overall symptom improvement and reduced burden, with most reporting satisfaction with gene therapy at Weeks 24 (80%), 52 (86%), and 104 (86%).

Regarding dietary alternatives to uncooked cornstarch (UCCS), a randomized, triple-blind, phase I/II crossover study evaluated sweet manioc starch (SMS) in 11 individuals with GSDIa (mean age 21.6 ± 4.3 years). The average fasting period was 8.2 ± 2.0 hours for SMS versus 7.7 ± 2.3 hours for UCCS (p = 0.04), with SMS maintaining euglycemia for a greater period over UCCS. No significant differences were observed in total cholesterol, HDL, triglycerides, or uric acid levels between arms, and no severe adverse events were reported, with SMS emerging as a non-inferior alternative to UCCS. An in vitro study further identified additional starch sources — including sweet manioc starch samples — as possible therapeutic alternatives for GSDIa in addition to traditional UCCS, noting that a clinical trial is warranted to compare specific samples and determine the impact of sugar trace in the same dietary source of starch.

Long-term natural history data underscore the progressive complications that treatment must address. A 17-year longitudinal case report of a genetically confirmed GSDIa patient documented a temporal sequence of renal injury in which tubulointerstitial changes preceded overt glomerular involvement: proteinuria emerged at age 6 years, followed by declining estimated glomerular filtration rate and overt Fanconi syndrome in adolescence, with progression to chronic kidney disease stage 3b in early adulthood. Renal biopsy revealed abundant glycogen granule deposition in renal tubular epithelial cells and extensive tubulointerstitial pathology, with glomeruli exhibiting only secondary focal segmental sclerotic-like changes. A separate case report described a 26-year-old male with GSDIa who progressed to end-stage kidney disease requiring hemodialysis, complicated by refractory anemia attributed to renal anemia, blood loss during each hemodialysis session, and inappropriately elevated hepcidin levels from multiple hepatic adenomas; anemia resolved within three months following a switch from oral sodium ferrous citrate to intravenous saccharated ferric oxide combined with aggressive treatment of renal anemia. These cases collectively illustrate that, without adequate metabolic control, GSDIa carries a risk of progressive hepatic and renal complications over decades.

GENGLYCOS's Long-Term Data: A New Era for GSDIa Management

The recent publication of 96-week data for GENGLYCOS (pariglasgene brecaparvovec-opnr) in The Journal of Inherited Metabolic Disease underscores a pivotal moment for individuals living with glycogen storage disease type Ia (GSDIa). This gene therapy, now FDA-approved for patients aged eight and older, offers a profound shift from the relentless dietary management that has long defined life with GSDIa.

The core challenge in GSDIa is the deficiency of glucose-6-phosphatase, an enzyme critical for maintaining stable blood glucose. Historically, this has necessitated frequent, often overnight, consumption of uncooked cornstarch to prevent life-threatening hypoglycemia. The published data reveal a mean 61% reduction in daily cornstarch intake, with a remarkable 33-42% of patients achieving complete elimination of nighttime dosing. This is not merely a numerical improvement; it translates directly into enhanced quality of life, better sleep, and reduced social burden for patients and their families.

However, the journey with gene therapy is not without its nuances. Clinical trials have shown that vector-induced inflammatory responses may necessitate corticosteroid administration, a factor requiring careful consideration in patient management. Furthermore, the inherent clinical and biochemical heterogeneity among GSDIa patients suggests that while the therapy offers broad benefit, individual responses may vary, underscoring the importance of personalized monitoring. Even with significant reductions in cornstarch, some patients may still experience blood sugar fluctuations, emphasizing the continued need for expert dietary guidance post-treatment to optimize long-term outcomes. This comprehensive long-term data provides critical insights for clinicians and patients navigating this transformative therapeutic landscape.